Disparities in clinical features and outcomes of peripartum cardiomyopathy in high versus low prevalent regions in Nigeria

Kamilu M. Karaye1,2,3,4*, Naser A. Ishaq1, Hadiza Sai’du2-5, Sulaiman A. Balarabe6, Bashir G. Ahmed6, Umar G. Adamu7, Idris Y. Mohammed8, Isa Oboirien9, Ejiroghene M. Umueri10, Abaram C. Mankwe11, Vincent Y. Shidali12, Sotonye Dodiyi-Manuel13, Paschal Njoku14, Taiwo Olunuga15, Veronica Josephs16, Amam C. Mbakwem17, Okechukwu S. Ogah18, Jamilu Tukur19, Basil Okeahialam20, Simon Stewart21, Michael Henein3, Karen Sliwa4 and Peripartum Cardiomyopathy in Nigeria (PEACE) Registry Investigators

1Department of Medicine, Aminu Kano Teaching Hospital/Kano, Nigeria; 2Department of Medicine, Bayero University, Kano, Nigeria; 3Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden; 4Hatter Institute for Cardiovascular Research in Africa & Chi, Cape Town, South Africa; 5Department of Medicine, Murtala Mohammed Specialist Hospital, Kano, Nigeria; 6Department of Medicine, Muhammad Abdullahi Wase Specialist Hospital, Kano, Nigeria; 7Department of Medicine, Federal Medical Centre, Bida, Nigeria & Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa; 8Department of Chemical Pathology, Aminu Kano Teaching Hospital, Medicine Bayero University, Kano, Nigeria; 9Department of Medicine, Dalhatu Araf Specialist Hospital, Lafia, Nigeria; 10Department of Medicine, Delta State University Teaching Hospital, Oghara, Nigeria; 11Department of Medicine, Federal medical centre, Yenagoa, Yenagoa, Nigeria; 12Department of Medicine, Federal Medical Center, Keffi, Nigeria; 13Department of Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria; 14University of Nigeria Teaching Hospital, Enugu, Nigeria; 15Department of Medicine, Federal medical centre, Abeokuta, Nigeria; 16Department of Medicine, University of Benin Teaching Hospital, Benin, Nigeria; 17Department of Medicine, University of Lagos, Lagos, Nigeria; 18Department of Medicine, University College Hospital, Ibadan, Nigeria; 19Department of Obstetrics and Gynaecology, Bayero University, Kano, Nigeria; 20Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria; and 21Torrens University Australia, Adelaide, South Australia, Australia

Abstract

Aims The prospective, multicentre Peripartum Cardiomyopathy in Nigeria (PEACE) registry originally demonstrated a high prevalence of peripartum cardiomyopathy (PPCM) among patients originating from Kano, North-West Nigeria. In a post hoc analysis, we sought to determine if this phenomenon was characterized by a differential case profile and outcome among PPCM cases originating elsewhere.

Methods and results Overall, 199 (81.6%) of a total 244 PPCM patients were recruited from three sites in Kano, compared with 45 patients (18.4%) from 11 widely dispersed centres across Nigeria. Presence and extent of ventricular myocardial remodelling during follow-up, relative to baseline status, were assessed by echocardiography. During median 17 months follow-up, Kano patients demonstrated significantly better myocardial reverse remodelling than patients from other sites. Overall, 50.6% of patients from Kano versus 28.6% from other regions were asymptomatic (P = 0.029) at study completion, with an accompanying difference in all-cause mortality (17.6% vs. 22.2% respectively, P = 0.523) not reaching statistical significance. Alternatively, 135/191 (84.9%) of Kano patients had selenium deficiency (<70 µg/L), and 46/135 (34.1%) of them received oral selenium supplementation. Critically, those that received selenium supplementation demonstrated better survival (6.5% vs. 21.2%; P = 0.025), but the supplement did not have significant impact on myocardial remodelling.

Conclusions This study has shown important non-racial regional disparities in the clinical features and outcomes of PPCM patients in Nigeria, that might partly be explained by selenium supplementation.

Keywords Peripartum cardiomyopathy; Regional disparities; Outcomes; Selenium; PEACE registry

Received: 19 January 2021; Revised: 9 April 2021; Accepted: 23 May 2021
*Correspondence to: Kamilu Karaye, Department of Medicine, Aminu Kano Teaching Hospital/Bayero University, PO Box 4445, Kano, Nigeria. Phone: +2348037042171. Email: kkaraye@yahoo.co.uk
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction

Peripartum cardiomyopathy (PPCM) is a disease with an epidemiology that varies widely across countries and regions. For example, incidence rates as low as 1 in 1000 live births in South Africa, 1 in 3189 live births in the USA, and 1 in 20 000 deliveries in Japan have been reported. The Peripartum Cardiomyopathy in Nigeria (PEACE) registry, the largest study of its kind, has also recently reported a wide variation in the incidence of PPCM across this populous country in West Africa. Specifically, this national, prospective, multicentre study demonstrated one case of PPCM per 96 deliveries in the city of Kano (an ancient and highly populous city located in North-West Nigeria). This is the highest ever-reported prevalence (globally) of PPCM to date. This contrasted to a low of one case per 2700 deliveries in the city of Makurdi located in North-Central Nigeria. Accordingly, of the 244 consecutively recruited patients with complete follow-up in PEACE registry, most cases were from the three study sites located in Kano. As originally reported, the independent risk factors for PPCM were a lack of formal education, underweight, unemployment status, and pre-eclampsia. However, the very high prevalence of PPCM in North-West Nigeria is of both clinical and public health significance. Regional and racial disparities in the outcomes of PPCM have also been reported previously. In the Investigations of Pregnancy-Associated Cardiomyopathy (IPAC) study, clinical outcomes were significantly worse in Black women as only 59% achieved left ventricular (LV) function recovery compared with 77% of those with a Caucasian or other background. Moreover, 26% of Black women had an event or demonstrated a final LV ejection fraction (LVEF) of <35%, compared with 8% of the rest. Furthermore, based on the European Society of Cardiology (ESC) PPCM registry, comprising cases from 49 countries in Europe, Africa including Nigeria, the Asian Pacific, and the Middle East, Sliwa and colleagues also reported regional differences in PPCM-related mortality. Specifically, they found a much higher death rate in the Middle East compared with other regions. In the original report of the PEACE registry, we also described elevated mortality rates accompanied by low rates of recovery of LV function in Nigeria overall. However, we did not specifically examine if these were driven by key regional differences.

Aims

Given the potentially important disparity in the number of PPCM patients located across Nigeria (with a predominance of cases occurring in the North-West city of Kano), we performed a post hoc analysis of the PEACE registry. Specifically, we compared the clinical profile and subsequent outcomes of those PPCM patients recruited in Kano versus the rest of Nigeria. We hypothesized that such an analysis would reveal potentially important insights into the causes and consequences of PPCM in Kano and other regions of the world in which PPCM remains highly prevalent.

Methods

The PEACE registry was a multicentre longitudinal study carried out in 14 sites spread across the geopolitical zones in Nigeria (Figures 1 and 2). The Steering Committee of the Registry designed and oversaw the conduct of the study, which was carried out in accordance with a previously reported protocol and statistical analysis plan. The study conformed to the ethical guidelines of the Declaration of Helsinki on the principles for medical research involving human subjects and was approved by the Ethics Committee at each site. The first author, who had unrestricted access to the data, prepared the first draft of the manuscript. All authors made the decision to submit the manuscript for publication and testify to the standard of conduct of the study. This paper is a post hoc analysis of PEACE registry data, and the detailed study protocol has already been published but summarized below.

Study participants

To be eligible for inclusion, all study participants had to be patients with a confirmed diagnosis of PPCM at any one of the participating sites. PPCM was defined as ‘an idiopathic cardiomyopathy presenting with signs or symptoms of heart failure (HF) secondary to LV systolic dysfunction, towards the end of pregnancy or in the early months following delivery, where no other cause of HF is found. It is a diagnosis of exclusion. The LV may not be dilated but the LVEF is reduced below 45%’. In this study, patients were required to have developed HF symptoms from the 28th week of gestation if pregnant and up to the first 5 months postpartum [New York Heart Association (NYHA) functional classes II, III, or IV (for new patients only)], to have LVEF below 45% at enrollment, an age of at least 18 years, and a written informed consent. We also enrolled into the study PPCM patients who were being treated and followed-up at any participating centre before the commencement of the study, regardless of the presence of symptoms, if they had satisfied the other inclusion criteria. We excluded patients who lacked reliable contact phone numbers, to minimize loss to follow-up.

We encouraged the investigators to prescribe standard and routinely available HF drug therapies in Nigeria. These included a diuretic, beta-blocker, angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker or nitrate-hydralazine combination, and a mineralocorticoid receptor antagonist, unless such use was contraindicated or
resulted in unacceptable side effects. In addition, drug doses were individually tailored, in accordance with guideline recommendations.\textsuperscript{13}

Prevalence of peripartum cardiomyopathy patients in Kano with LVEF <45% at 6 months postpartum were also screened for selenium deficiency (<70 μg/L) and included in the
Selenium Supplementation Trial, which is a sub-study of the PEACE registry. Patients randomized to the treatment arm in the trial received oral selenium supplementation at a dose of 200 μg/day for 3 months and were included in this post hoc analysis. The other study sites in PEACE registry did not participate in the selenium trial.

Table 1 Baseline characteristics

| Variables                      | Kano sites (N = 199) | Other zones (N = 45) | P-value |
|--------------------------------|----------------------|----------------------|---------|
| Demographic characteristics    |                      |                      |         |
| Age, years                     | 29.3 ± 7.7           | 30.8 ± 8.0           | 0.013*  |
| Age <20 years                  | 41 (20.6%)           | 3 (6.7%)             | 0.031*  |
| Age ≥30 years                  | 29 (14.6%)           | 13 (28.9%)           | 0.034*  |
| Hausa/Fulani ethnicity         | 195 (98.0%)          | 2 (4.4%)             | <0.001* |
| Last child birth, months       | 12 (6-24)            | 4 (3-9)              | 0.001*  |
| Twins                          | 41 (20.6%)           | 2 (4.4%)             | 0.009*  |
| Multiparity                    | 140 (70.4%)          | 10 (22.2%)           | 0.364   |
| Illiteracy                     | 63 (31.7%)           | 7 (15.6%)            | 0.043*  |
| Unemployment                   | 152 (76.4%)          | 25 (55.6%)           | 0.009*  |
| Clinical characteristics       |                      |                      |         |
| NYHA II-IV                     | 147 (73.9%)          | 41 (91.1%)           | 0.011*  |
| Systolic BP, mmHg              | 109 ± 17             | 107 ± 17             | 0.612   |
| Diastolic BP, mmHg             | 76.2 ± 14            | 74 ± 16              | 0.416   |
| Heart rate/min, mmHg           | 105 ± 71             | 99 ± 22              | 0.359   |
| Body mass index, kg/m²         | 20.2 ± 5.2           | 20.9 ± 8.9           | 0.500   |
| Preeclampsia                   | 39 (19.6%)           | 4 (8.9%)             | 0.125   |
| Pneumonia                      | 9 (4.5%)             | 4 (8.9%)             | 0.267   |
| Stroke                         | 7 (3.5)              | 0                    | 0.355   |
| Atrial fibrillation            | 3 (1.5%)             | 1 (2.2%)             | 0.999   |
| Mural thrombus                 | 1 (0.5%)             | 2 (4.4%)             | 0.177   |

Values are expressed as means ± standard deviations or proportions in parentheses. NYHA, New York Heart Association functional classes.

*P-value is statistically significant.

Seleni...
2018. The study cohort was followed-up until 31 March 2019 [median of 17 (IQR 14–20) months], except 18 patients (6.9%) who were lost to follow-up, as shown in Figure 2. Of the 244 participants with complete follow-up, 199 (81.6%) were recruited from the three study centres in Kano City, North-West Nigeria, while the remaining 45 (18.4%) were recruited from the North-Central (19; 7.8%), South-West (15; 6.2%), South-South (10; 4.1%), and South-East (1; 0.4%) geopolitical zones as shown in Figure 1. The baseline demographic and clinical characteristics of the patients in the two groups are summarized and compared in Table 1. This table shows that patients from Kano were younger, presented to the study sites later since last childbirth and were less symptomatic than those from the other sites, at presentation. Stroke was exclusively found among 3.5% of patients in Kano, while atrial fibrillation and mural thrombus were uncommon in both groups.

Table 2 shows the pattern of HF treatment within the two groups. Kano patients received less angiotensin converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARB) and beta-blockers during the study, than those from other sites. A high proportion (>85%) of patients in both groups received a loop-diuretic; with one additional patient in Kano receiving bendrofluazide 2.5 mg once daily. Overall, 163 (66.8%) patients also received digoxin in the study; most of them (149; 91.4%) at the dose of 0.125 mg daily. At presentation, warfarin use was more common among patients from other regions (24.4%) compared with those from Kano (2.5%) ($P < 0.001$). A reverse pattern of antiplatelet treatments (aspirin or clopidogrel) (27.6% for Kano vs. 13.3% rest; $P = 0.045$) was observed. In addition, 135 (84.9%) of 191 PPCM patients in Kano with LVEF <45% at 6 months post-partum had selenium deficiency (<70 μg/L). Of these, 46 (34.1%) received oral selenium supplementation at a dose of 200 μg/day for 3 months.

Table 3 and Figure 3 shows that Kano patients had larger cardiac chambers and worse right heart function at enrolment. However, they showed greater reverse remodelling of all cardiac chambers than patients from the other zones. These observations were independent of the selenium supplementation as shown in Table 4.

The main study outcomes are summarized in Table 5, and the pattern of mortality pattern is illustrated in the Kaplan–Meier curve ($P$-value = 0.180) in Figure 4. Figure 5 shows that worsening HF was the commonest known cause of death in the two groups followed by sudden death. Alternatively, the exact causes of 40% of deaths in the other regions were unknown. In addition, mortality [3/46 (6.5%) vs. 42/198 (21.2%); $P = 0.025$] (Table 4) and HF symptoms at the last profiling [18/46 (39.1%) vs. 133/198 (67.2%); $P < 0.001$] were significantly less in the group that received selenium supplementation as compared with the remaining patients. Further analysis shows that 83 of 164 (50.6%) patients from Kano and 10 of 35 (28.6%) from other zones were

---

**Table 3: Myocardial remodelling**

| Variable               | Kano            | Other zones | P-value (baseline vs. last profiling) | Kano            | Other zones | P-value (last profiling vs. baseline) |
|------------------------|-----------------|-------------|--------------------------------------|-----------------|-------------|---------------------------------------|
| LA dimension, mm       | 45.0 ± 6.0      | 74.0 ± 8.3  | 0.005*                               | 42.4 ± 5.9      | 77.4 ± 8.3  | 0.001*                                |
| Indexed LV end-diastolic dimension, mm² | 29.3 ± 4.0 | 30.9 ± 4.3 | 0.003*                               | 29.3 ± 4.0      | 30.9 ± 4.3  | 0.003*                                |
| LVEF, %                | 38.0 ± 6.2      | 37.7 ± 6.4  | 0.001*                               | 35.3 ± 6.4      | 35.3 ± 6.4  | 0.001*                                |
| RV end-diastolic dimension, mm | 14.1 ± 3.6 | 16.8 ± 4.3 | 0.001*                               | 14.1 ± 3.6      | 16.8 ± 4.3  | 0.001*                                |
| Pulmonary artery systolic pressure, mmHg | 36.0 ± 28.7 | 25.4 ± 16.5 | <0.001*                              | 36.0 ± 28.7      | 25.4 ± 16.5 | <0.001*                              |

Values are expressed as means ± standard deviations. LA, left atrial volume; LV, left ventricle; LVEF, left ventricular ejection fraction.

* $P$-value is statistically significant.
asymptomatic ($P = 0.029$) at the completion of the study. The asymptomatic patients (NYHA I) had significantly higher mean LVEF (48.6 ± 11.9%) than those with NYHA II to IV (39.3 ± 13.3%) ($P < 0.001$).

The result of the Cox proportional hazard regression model for mortality is presented in Table 6. It shows that being from Kano, younger by 0.2 years at recruitment, and regular use of beta-blockers censored at the sixth follow-up month were all significantly associated with lower mortality, while regular use of digoxin censored at the sixth follow-up month was associated with higher mortality, after accounting for time since last childbirth, and use of ACE-I or an ARB and spironolactone at the sixth month of follow-up.

**Discussion**

In this multicentre longitudinal study spread across the geopolitical zones in Nigeria, 81.6% of the patients were consecutively recruited from the three study centres in the North-Western Nigerian City of Kano. We conducted a post hoc analysis based on patient origin to determine if the high prevalence of PPCM in Kano was characterized by a differential case profile and outcomes.

Our results showed that as compared with patients from other geopolitical zones, those from Kano presented to the study centres for confirmation of diagnosis and initiation of appropriate treatments later since last childbirth, had larger cardiac chambers, worse LV and RV systolic function, and received less HF medical therapy, at recruitment. However, about one-quarter of the Kano patients also received a selenium supplement for 3 months, which seemed to be associated with 3.3-fold lower prevalence of mortality. However, the selenium supplement did not appear to have impact on reverse remodelling of cardiac chambers. These findings need to be interpreted with some caution given the fact that they were derived from a post hoc analysis of an observational study.

Overall, patients from Kano were less symptomatic throughout the study and appeared to significantly have better positive reverse remodelling of both the sizes and function of cardiac chambers than those from the other regions. Although the reasons for the latter findings are not yet clear, they seem to be unrelated to the selenium supplementation as illustrated by our limited analyses of the cohorts with and without selenium supplementation. For whatever reasons, PPCM patients from Kano seemed to have the typical PPCM syndrome, which is characterized by significant though variable positive myocardial reverse remodelling. LV function recovery in PPCM patients, that was variably defined, was previously reported as 29.4% at 1 year in Nigeria, 71% in the USA, 21% at 6 months in South Africa, 28% at 2 years in Haiti, and 95.5% at 5 years in Germany, of follow-up, respectively. Consistent with the absence of focal myocardial damage on late gadolinium enhancement imaging, most PPCM patients are expected to exhibit significant improvements in LV and RV systolic function with favourable changes in LV and RV mass and volumes. As previously observed, significant myocardial function recovery in PPCM patients occurs even when HF treatment is suboptimal.
Table 4 Baseline characteristics and main outcomes of PPCM patients stratified according to use of selenium supplement

| Variables                                      | Selenium supplement (N = 46) | No selenium, all sites (N = 198) | P-value | Kano, no selenium (N = 153) | Other zones (N = 45) | P-value |
|------------------------------------------------|-------------------------------|----------------------------------|---------|-------------------------------|----------------------|---------|
| **Demographic characteristics**                |                               |                                   |         |                               |                      |         |
| Age, years                                     | 29.6 ± 7.3                    | 28.7 ± 7.2                       | 0.882   | 31.3 ± 6.5                    | 30.8 ± 8.0           | 0.006   |
| Age <20 years                                   | 6 (13.0%)                     | 3 (6.7%)                         | 0.329   | 35 (22.9%)                    | 3 (6.7%)             | 0.017*  |
| Age >30 years                                   | 7 (15.2%)                     | 13 (28.9%)                       | 0.662   | 22 (14.4%)                    | 13 (28.9%)           | 0.028*  |
| Last child birth <5 months                     | 7 (15.2%)                     | 39 (19.7%)                       | 0.728   | 25 (16.3%)                    | 14 (31.1%)           | 0.001*  |
| Multiparity                                     | 31 (67.4%)                    | 144 (72.7%)                      | 0.469   | 109 (71.2%)                   | 10 (22.2%)           | 0.387   |
| Unemployment                                    | 14 (30.4%)                    | 53 (26.8%)                       | 0.616   | 120 (78.4%)                   | 25 (55.6%)           | 0.002*  |
| **Clinical characteristics**                   |                               |                                   |         |                               |                      |         |
| NYHA II-IV symptoms                            | 31 (67.4%)                    | 157 (79.3%)                      | 0.084   | 116 (75.8%)                   | 41 (91.1%)           | 0.035%  |
| Systolic BP, mmHg                              | 108 ± 16                      | 109 ± 17                         | 0.919   | 109 ± 17                      | 107 ± 17             | 0.543   |
| Diastolic BP, mmHg                             | 74 ± 12                       | 76 ± 15                          | 0.609   | 77 ± 15                       | 74 ± 16              | 0.269   |
| Heart rate/min                                 | 96 ± 18                       | 106 ± 70                         | 0.671   | 102 ± 18                      | 99 ± 22              | 0.881   |
| Body mass index, kg/m²                         | 19.8 ± 6.4                    | 20.5 ± 5.9                       | 0.582   | 19.9 ± 5.6                    | 20.9 ± 8.9           | 0.549   |
| Preeclampsia                                   | 13 (28.3%)                    | 30 (15.2%)                       | 0.037*  | 26 (17.0)                     | 4 (8.9%)             | 0.241   |
| Pneumonia                                      | 3 (6.5%)                      | 10 (5.1%)                        | 0.716   | 6 (3.9%)                      | 4 (8.9%)             | 0.239   |
| Stroke                                         | 3 (6.5%)                      | 10 (5.1%)                        | 0.126   | 4 (2.6%)                      | 0                  | 0.576   |
| Atrial fibrillation                            | 0                             | 4 (2.0%)                         | 0.862   | 3 (2.0%)                      | 1 (2.2%)             | 0.999   |
| **Treatment**                                  |                               |                                   |         |                               |                      |         |
| Beta-blockers                                  | 11 (23.9%)                    | 104 (52.5%)                      | 0.001*  | 35 (22.9%)                    | 13 (28.9%)           | 0.408   |
| ACE-I or ARB                                   | 24 (52.2%)                    | 54 (27.3%)                       | 0.026*  | 47 (30.7%)                    | 27 (60.0%)           | <0.001* |
| Digoxin                                        | 33 (71.7%)                    | 84 (42.2%)                       | 0.359   | 101 (66.0%)                   | 29 (64.4%)           | 0.803   |
| Spironolactone                                 | 38 (82.6%)                    | 99 (50.0%)                       | 0.304   | 138 (90.2%)                   | 42 (93.3%)           | 0.769   |
| **Echocardiography**                           |                               |                                   |         |                               |                      |         |
| LA dimension, mm                               | 45.1 ± 6.5                    | 44.4 ± 6.5                       | 0.907   | 45.0 ± 5.8                    | 42.0 ± 8.3           | 0.007*  |
| Indexed LV end-diastolic dimension, mm/m²      | 41.6 ± 5.6                    | 41.8 ± 6.6                       | 0.310   | 42.7 ± 6.0                    | 38.9 ± 7.8           | 0.001*  |
| LVEF, %                                        | 30.9 ± 7.7                    | 29.1 ± 7.9                       | 0.345   | 28.8 ± 7.8                    | 30.8 ± 8.0           | 0.124   |
| RV end-diastolic dimension, mm                 | 42.7 ± 7.9                    | 42.9 ± 8.4                       | 0.771   | 43.5 ± 7.5                    | 39.7 ± 11.3          | 0.021*  |
| Tricuspid annular plane systolic excursion, mm| 14.1 ± 3.7                    | 14.8 ± 4.3                       | 0.364   | 14.2 ± 3.6                    | 16.9 ± 5.8           | <0.001* |
| Pulmonary artery systolic pressure, mmHg       | 42.8 ± 19.0                   | 47.5 ± 23.0                      | 0.432   | 49.8 ± 2.1                    | 37.8 ± 18.1          | 0.011*  |
| **Outcomes**                                   |                               |                                   |         |                               |                      |         |
| All-cause mortality                            | 3 (6.5%)                      | 42 (21.2%)                       | 0.025*  | 32 (20.9%)                    | 10 (22.2%)           | 0.850   |
| All-cause rehospitalization                    | 3 (6.5%)                      | 13 (6.6%)                        | 0.999   | 13 (8.5%)                     | 13 (28.9%)           | <0.001* |
| LVEF ≥55%                                      | 33 (71.7%)                    | 124 (62.6%)                      | 0.422   | 97 (63.4%)                    | 27 (60%)             | 0.653   |

Values are expressed as means ± standard deviations or proportions with percentages in parentheses. BP, blood pressure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional classes. *P-value is statistically significant.
In the present study, the proportion of specific causes of deaths due to worsening HF and sudden deaths were similar in the two groups, although the proportion of unknown causes of deaths was lower in Kano than the other study sites, perhaps due to a more meticulous data collection. The factors independently associated with reduced risk of mortality in this study included Kano residency, a unit change in age, and regular use of beta-blockers at the sixth follow-up month. The effect of beta-blockers seems to persist as an independent correlate of mortality in our PEACE registry cohort regardless of the Cox proportional hazard regression model. However, the reduction in the risk of all-cause mortality by 97% among the PPCM patients simply by Kano residency, who correspondingly have a significantly better myocardial recovery, is an important novel finding that needs further elucidation.

Although the reasons behind the regional variations associated with PPCM are not yet clear, it seems sensible to hypothesize that they are caused by an interplay between environmental and genetic factors. A key environmental factor in PPCM could be selenium deficiency, which was recently found in up to 85% of PPCM patients in Kano, and associated with 3.3-fold lower prevalence of mortality. In the first-ever Selenium Supplementation Trial in PPCM however, we showed that a 3 month course of selenium supplementation significantly reduced HF symptoms, with a positive trend towards survival benefit but without significant impact on myocardial reverse remodelling. In contrast, selenium deficiency was found in only 22% of apparently healthy puerperal women in Kano. Another possibility is a genetic factor with racial significance such as the TT genotype of guanine nucleotide–binding proteins β-3 subunit. This TT genotype was associated with lower LVEF at 6 and 12 months in women with PPCM, that was particularly evident in Blacks, but has not yet been assessed in Nigerian PPCM patients. Thus, it seems reasonable to suggest that the PPCM syndrome in Kano, and by extension North-West Nigeria (given the similar PPCM incidence rate), is different from that of the other zones in the country. These findings further support the notion that PPCM is a heterogeneous disease, with intra- and inter-regional epidemiological variations.

In our cohort, more than 60% of the patients were receiving digoxin while less than 30% were receiving beta-blockers at presentation to the referral study centres, although the frequency of atrial fibrillation was low, and therefore, the prescription pattern was not clearly in conformity with standard HF treatment guidelines. The prescription pattern improved at the last profiling, though sub-optimally, while the patients received care at the study centres. The serum levels of digoxin were not routinely monitored in PEACE registry although nearly all patients on digoxin received the low daily dose of 0.125 mg. Our result on the relationship between

### Table 5: Study outcomes

| Variables          | Kano sites (N = 199) | Other zones (N = 45) | P-value |
|--------------------|----------------------|----------------------|---------|
| All-cause mortality| 35 (17.6%)           | 10 (22.2%)           | 0.523   |
| All-cause rehospitalization | 17 (8.5%)          | 0                    | 0.055   |
| LVEF ≥55%          | 39 (23.8%)           | 6 (17.1%)            | 0.394   |

Values are expressed as proportions with percentages in parentheses. LVEF, left ventricular ejection fraction.

Figure 4 Kaplan–Meier survival curves. Number of patients at risk of mortality. Kaplan–Meier survival curves showing patients at risk of mortality at each month of follow-up in Kano and other study sites.
digoxin and mortality should be interpreted with caution because it was derived from a post hoc analysis of an observational study. The expert panel on the management of PPCM of the Heart Failure Association of the European Society of Cardiology (ESC) and the Task Force on HF of the ESC both recommend that digoxin may be considered in patients in sinus rhythm with symptomatic HF with reduced EF, to reduce the risk of both all-cause and HF hospitalizations, mainly based on the results of the DIG (Digitalis Investigation Group) trial. Furthermore, a post hoc analysis of the DIG trial showed that digoxin therapy was associated with a 23% increase in the relative risk (absolute difference of 5.8%) of death from any cause among women, but not men, with HF and depressed LV systolic function. However, another post hoc analysis of the DIG trial then showed a beneficial effect of digoxin on morbidity and no excess mortality in women at serum concentrations from 0.5 to 0.9 ng/mL, whereas serum concentrations ≥1.2 ng/mL seemed to be harmful.

For several logistical reasons, patients in the PEACE registry cohort were sub-optimally managed with guidelines-recommended HF medications, which are associated with improved clinical outcomes. In addition, none of the patients received bromocriptine or any device therapy for HF. On the contrary, at the time of diagnosis, 76% of PPCM patients in a German PPCM cohort were on a combination of a beta-blocker, an angiotensin converting enzyme inhibitor or angiotensin receptor blockers and a mineralocorticoid receptor antagonist, 83% received bromocriptine and 25% received HF device treatment; their usage probably explains the relatively low mortality rate (1.5%) and high LV systolic function recovery (95.5%) reported at 5 years.

Stroke was exclusively found in up to 3.5% of the patients in Kano at presentation, in spite of the fact that there were no significant between-group differences for the frequency of atrial fibrillation and mural thrombi. This finding might be explained by the more frequent use of prophylactic warfarin in the other zones than Kano (24.4% vs. 2.5%) at presentation, which is recommended for treatment of PPCM in the context of poor LV function (LVEF <35%) during or immediately after pregnancy.

**Limitations**

It is important to emphasize the post hoc nature of our analyses and the overall pragmatic design of the PEACE registry; given the study location and the inherent difficulties in optimally diagnosing and treating PPCM on the African continent. Accordingly, although it is desirable to collect...
genetic, serum selenium, and other relevant biomarkers that could explore the regional differences between study participants, due to prohibiting logistical reasons, these were beyond the scope of the original PEACE registry. We hope to address these and other important limitations in future studies.

Conclusions

This study confirms the existence of a significant non-racial regional variation in the epidemiology of PPCM in Nigeria. About one-quarter of the PPCM patients from Kano received selenium supplementation. Pending confirmation from definitive studies, it appears probable that such therapy contributed to their significantly better survival than those from the other geopolitical zones. However, PPCM patients from Kano also had significantly better myocardial remodeling than those from the other geopolitical zones that was independent of the selenium supplementation. This important finding also merits further investigation.

Funding

The authors acknowledge with gratitude receiving funds from the following organizations: Dantata Group of Companies (Nigeria), Ammasco International Ltd (Nigeria), and Fortune Oil Mills Nigeria Ltd. S.S. is supported by the National Health and Medical Research Council of Australia (GNT1135894).

References

1. Karaye KM, Habib AG, Sliwa K. Epidemiology of peripartum cardiomyopathy in Africa. Intern Cardiobvasc Forum J 2018; 15: 6–11.
2. Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 1995; 25: 118–123.
3. Mielniczuk LM, Williams K, Davis DR, Tang AS, Lemery R, Green MS, Gollob MH, Haddad H, Birnie DH. Frequency of peripartum cardiomyopathy. Am J Cardiol 2006; 97: 1765–1768.
4. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, Nakatani S, Murohara T, Tomoike H, Ikeda T. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J 2011; 75: 1975–1981.
5. Karaye KM, Ishaq NA, Sa’idu H, Balarabe SA, Talle MA, Isa MS, Adamu UG, Umar H, Okolie HI, Shehu MN, Mohammed IY, Sanni B, Ogah OS, Oboirien I, Umueri EM, Mankwe AC, Shidali VY, Njoku P, Dodiyi-Manuel S, Shogade TT, Olunuga T, Oji J, Josephs V, Mbakwem AC, Tukur J, Isezuo SA. PEACE Registry Investigators. Incidence, clinical characteristics, and design for the peripartum cardiomyopathy in Nigeria registry. ESC Heart Fail 2020; 7: 235–243.
6. National Population Commission. population.gov.ng. Archived from the original on October 10, 2017. Retrieved October 10, 2017.
7. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, Modi K, Alexis JD, Ramani GV, Semigran MJ, Haythe J, Markham DW, Marek J, Gorcsan J, Wu WC, Lin Y, Halder I, Pisarcik J, Cooper LT, Fett JD, IPAC Investigators. Clinical outcomes for peripartum cardiomyopathy in North America: Results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol 2015; 66: 905–914.
8. Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilﬁker-Kleiner D, Jackson AM, Maggioni AP, Laroche C, Regitz-Zagrosek V, Staufferberger M, Tavazzi L, Roos-Hesselink J, Sfeirovic P, van Spandonck-zwarts K, Mbakwem A, Boehm M, Mouquet PB, Johnson MR, Hamdan R, Ponikowski P, Veldhuisen DJ, McMurray JJ, Bauersachs J. Management and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J 2020; 41: 3787–3797.
9. Karaye KM, Sa’idu H, Balarabe SA, Ishaq NA, Adamu UG, Mohammed IY, Oboirien I, Umueri EM, Mankwe AC, Shidali VY, Njoku P, Dodiyi-Manuel S, Shogade TT, Olunuga T, Oji J, Josephs V, Mbakwem AC, Tukur J, Isezuo SA. PEACE Registry Investigators. Clinical features and outcomes of peripartum cardiomyopathy in Nigeria. J Am Coll Cardiol 2020; 76: 2352–2364.
10. Karaye KM, Mohammed IY, Ogah OS, Ishaq NA, Sanni B, Abubakar H, Mohammed BL, Abdulsalam T, Tukur J, Mohammed IY. Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial. BMC Cardiovasc Disord 2020; 20: 457.
11. Lang RM, Badano LP, Mor-Avi V, Aﬁalio J, Armstrong A, Ernande L, Fleckskamp FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Maruyu D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the European Association of Cardiovascular Imaging. Eur Heart J Suppl 2018; 20: e30–e87.
12. Sliwa K, Hilﬁker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, Veldhuisen DJ, Watkins H, Shah AJ, Sfeirovic P, Elkaayam U, Pankwiet S, Papp Z, Mouquet F, McMurray JJ. Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12: 767–778.
13. Bauersachs J, König T, van der Meer P, Petrie MC, Hilﬁker-Kleiner D, Mbakwem A, Hamdan R, Jackson AM, Forsyth P, de Boer RA, Mueller C, Ahlers CR, Lund LH, Piepoli MF, Heymans S, Chioncel O, Anker SD, Ponikowski P, Sfeirovic PM, Johnson MR, Mebazaa A, Sliwa K. Pathophysiology, diagnosis, management and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2019; 21: 827–843.
14. Karaye KM, Sa’idu H, Balarabe SA, Ishaq NA, Sanni B, Abubakar H, Mohammed BL, Abdulsalam T, Tukur J, Mohammed IY. Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial. BMC Cardiovasc Disord 2020; 20: 457.
15. Lang RM, Badano LP, Mor-Avi V, Aﬁalio J, Armstrong A, Ernande L, Fleckskamp FA, Foster E, Goldstein SA Kuznetsova T, Lancellotti P, Maruyu D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the European Association of Cardiovascular Imaging. Eur Heart J Suppl 2018; 20: e30–e87.
for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015; 28: 1–39.
16. Karaye KM, Lindmark K, Henein MY. One-year survival in Nigerians with peripartum cardiomyopathy. *Heart Views* 2016; 17: 55–61.
17. Blauwet LA, Libhaber E, Forster O, Tibazarwa K, Mebazaa A, Hilfiker-Kleiner D, Sliwa K. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. *Heart* 2013; 99: 308–313.
18. Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, Schwab J, Berliner D, Pfister R, Michels G, Haghi-Kia A, Falk CS, Duncker D, Vetelmann C, Hilfiker-Kleiner D, Bauersachs J. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. *Eur J Heart Fail* 2019; 21: 1534–1542. [E-pub ahead of print].
19. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. *Mayo Proc* 2005; 80: 1602–1606.
20. Schelbert EB, Elkayam U, Cooper LT, Givertz MM, Alexis JD, Briller J, Felker GM, Chaparro S, Kealey A, Pisarcik J, Fett JD, McNamara DM. Investigations of Pregnancy Associated Cardiomyopathy (IPAC) Investigators. Myocardial damage detected by late gadolinium enhancement cardiac magnetic resonance is uncommon in peripartum cardiomyopathy. *J Am Heart Assoc* 2017; 6: e005472.
21. Karaye KM, Lindmark K, Henein MY. Right ventricular systolic dysfunction and remodelling in Nigerians with peripartum cardiomyopathy: a longitudinal study. *BMC Cardiovasc Disord* 2016; 16: 27.
22. Karaye KM, Yahaya IA, Lindmark K, Henein MY. Serum selenium and ceruloplasmin in Nigerians with peripartum cardiomyopathy. *Int J Mol Sci* 2015; 16: 7644–7654.
23. Sheppard R, Hsich E, Damp J, Elkayam U, Kealey A, Ramani G, Zucker M, Alexis JD, Horne BD, Hanley-Yanez K, Pisarcik J, Halder I, Fett JD, McNamara DM, IPAC Investigators. GNB3 C825T polymorphism and myocardial recovery in peripartum cardiomyopathy: results of the multicenter investigations of pregnancy-associated cardiomyopathy study. *Circ Heart Fail* 2016; 9: e002683.
24. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016; 18: 891–975.
25. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997; 336: 525–533.
26. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. *N Engl J Med* 2002; 347: 1403–1411.
27. Adams KF Jr, Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA, Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. *J Am Coll Cardiol* 2005; 46: 497–504.